Abstract
We hypothesize there are coagulation profile changes associated both with initiation of thromboporphylaxis (TPX) and with change in platelet levels in trauma patients at high-risk for venous thromboembolism (VTE). A total of 1203 trauma intensive care unit patients were screened with a VTE risk assessment profile. In all, 302 high-risk patients (risk assessment profile score ≥ 10) were consented for weekly thromboelastography. TPX was initiated between initial and follow-up thromboelastography. Seventy-four patients were analyzed. Upon admission, 87 per cent were hypercoagulable, and 81 per cent remained hypercoagulable by Day 7 (P = 0.504). TPX was initiated 3.4 ± 1.4 days after admission; 68 per cent received unfractionated heparin and 32 per cent received low-molecular-weight heparin. The VTE rate was 18 per cent, length of stay 38 (25-37) days, and mortality of 17.6 per cent. In all, 76 per cent had a rapid clotting time at admission versus 39 per cent at Day 7 (P < 0.001); correcting from 7.75 (6.45-8.90) minutes to 10.45 (7.90-15.25) minutes (P < 0.001). At admission, 41 per cent had an elevated maximum clot formation (MCF) and 85 per cent had at Day 7 (P < 0.001); increasing from 61(55-65) mm to 75(69-80) mm (P < 0.001). Platelets positively correlated with MCF at admission (r = 0.308, R<sup>2</sup> = 0.095, P = 0.008) and at Day 7 (r = 0.516, R<sup>2</sup> = 0.266, P < 0.001). Change in platelet levels correlated with change in MCF (r = 0.332, R<sup>2</sup> = 0.110, P = 0.005). In conclusion, hypercoagulability persists despite the use of TPX. Although clotting time normalizes, MCF increases in correlation with platelet levels. As platelet function is a dominant contributor to sustained trauma-evoked hypercoagulability, antiplatelet therapy may be indicated in the management of severely injured trauma patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 663-664 |
| Number of pages | 2 |
| Journal | American Surgeon |
| Volume | 81 |
| Issue number | 7 |
| State | Published - Jul 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Surgery
Cite this
Coagulation profile changes due to thromboprophylaxis and platelets in trauma patients at high-risk for venous thromboembolism. / Casey J, Allen; Murray, Clark R.; Meizoso, Jonathan P.; Juliet J, Ray; Laura F, Teisch; Xiomara, Ruiz; Mena M, Hanna; Gerardo A, Guarch; Manning, Ronald J.; Livingstone, Alan; Ginzburg, Enrique; Schulman, Carl I; Namias, Nicholas; Proctor, Kenneth G.
In: American Surgeon, Vol. 81, No. 7, 01.07.2015, p. 663-664.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Coagulation profile changes due to thromboprophylaxis and platelets in trauma patients at high-risk for venous thromboembolism
AU - Casey J, Allen
AU - Murray, Clark R.
AU - Meizoso, Jonathan P.
AU - Juliet J, Ray
AU - Laura F, Teisch
AU - Xiomara, Ruiz
AU - Mena M, Hanna
AU - Gerardo A, Guarch
AU - Manning, Ronald J.
AU - Livingstone, Alan
AU - Ginzburg, Enrique
AU - Schulman, Carl I
AU - Namias, Nicholas
AU - Proctor, Kenneth G
PY - 2015/7/1
Y1 - 2015/7/1
N2 - We hypothesize there are coagulation profile changes associated both with initiation of thromboporphylaxis (TPX) and with change in platelet levels in trauma patients at high-risk for venous thromboembolism (VTE). A total of 1203 trauma intensive care unit patients were screened with a VTE risk assessment profile. In all, 302 high-risk patients (risk assessment profile score ≥ 10) were consented for weekly thromboelastography. TPX was initiated between initial and follow-up thromboelastography. Seventy-four patients were analyzed. Upon admission, 87 per cent were hypercoagulable, and 81 per cent remained hypercoagulable by Day 7 (P = 0.504). TPX was initiated 3.4 ± 1.4 days after admission; 68 per cent received unfractionated heparin and 32 per cent received low-molecular-weight heparin. The VTE rate was 18 per cent, length of stay 38 (25-37) days, and mortality of 17.6 per cent. In all, 76 per cent had a rapid clotting time at admission versus 39 per cent at Day 7 (P < 0.001); correcting from 7.75 (6.45-8.90) minutes to 10.45 (7.90-15.25) minutes (P < 0.001). At admission, 41 per cent had an elevated maximum clot formation (MCF) and 85 per cent had at Day 7 (P < 0.001); increasing from 61(55-65) mm to 75(69-80) mm (P < 0.001). Platelets positively correlated with MCF at admission (r = 0.308, R2 = 0.095, P = 0.008) and at Day 7 (r = 0.516, R2 = 0.266, P < 0.001). Change in platelet levels correlated with change in MCF (r = 0.332, R2 = 0.110, P = 0.005). In conclusion, hypercoagulability persists despite the use of TPX. Although clotting time normalizes, MCF increases in correlation with platelet levels. As platelet function is a dominant contributor to sustained trauma-evoked hypercoagulability, antiplatelet therapy may be indicated in the management of severely injured trauma patients.
AB - We hypothesize there are coagulation profile changes associated both with initiation of thromboporphylaxis (TPX) and with change in platelet levels in trauma patients at high-risk for venous thromboembolism (VTE). A total of 1203 trauma intensive care unit patients were screened with a VTE risk assessment profile. In all, 302 high-risk patients (risk assessment profile score ≥ 10) were consented for weekly thromboelastography. TPX was initiated between initial and follow-up thromboelastography. Seventy-four patients were analyzed. Upon admission, 87 per cent were hypercoagulable, and 81 per cent remained hypercoagulable by Day 7 (P = 0.504). TPX was initiated 3.4 ± 1.4 days after admission; 68 per cent received unfractionated heparin and 32 per cent received low-molecular-weight heparin. The VTE rate was 18 per cent, length of stay 38 (25-37) days, and mortality of 17.6 per cent. In all, 76 per cent had a rapid clotting time at admission versus 39 per cent at Day 7 (P < 0.001); correcting from 7.75 (6.45-8.90) minutes to 10.45 (7.90-15.25) minutes (P < 0.001). At admission, 41 per cent had an elevated maximum clot formation (MCF) and 85 per cent had at Day 7 (P < 0.001); increasing from 61(55-65) mm to 75(69-80) mm (P < 0.001). Platelets positively correlated with MCF at admission (r = 0.308, R2 = 0.095, P = 0.008) and at Day 7 (r = 0.516, R2 = 0.266, P < 0.001). Change in platelet levels correlated with change in MCF (r = 0.332, R2 = 0.110, P = 0.005). In conclusion, hypercoagulability persists despite the use of TPX. Although clotting time normalizes, MCF increases in correlation with platelet levels. As platelet function is a dominant contributor to sustained trauma-evoked hypercoagulability, antiplatelet therapy may be indicated in the management of severely injured trauma patients.
UR - http://www.scopus.com/inward/record.url?scp=84936933015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936933015&partnerID=8YFLogxK
M3 - Article
C2 - 26140884
AN - SCOPUS:84936933015
VL - 81
SP - 663
EP - 664
JO - The American surgeon
JF - The American surgeon
SN - 0003-1348
IS - 7
ER -